Chardan Capital reissued their buy rating on shares of uniQure NV (NASDAQ:QURE) in a report released on Tuesday. The brokerage currently has a $12.00 price target on the stock.

A number of other research firms also recently issued reports on QURE. Leerink Swann reiterated an outperform rating and issued a $27.00 target price on shares of uniQure NV in a research report on Monday, August 29th. Piper Jaffray Cos. set a $16.00 target price on shares of uniQure NV and gave the stock a buy rating in a research report on Friday, August 19th. HC Wainwright began coverage on shares of uniQure NV in a research report on Thursday, August 4th. They issued a buy rating and a $21.00 target price for the company. Zacks Investment Research downgraded shares of uniQure NV from a hold rating to a sell rating in a research report on Thursday, August 4th. Finally, Jefferies Group set a $28.00 target price on shares of uniQure NV and gave the stock a buy rating in a research report on Thursday, July 28th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $25.80.

uniQure NV (NASDAQ:QURE) traded down 8.67% during trading on Tuesday, reaching $7.06. 336,268 shares of the company’s stock were exchanged. uniQure NV has a 1-year low of $6.63 and a 1-year high of $22.79. The company’s market capitalization is $177.41 million. The company’s 50-day moving average is $7.35 and its 200-day moving average is $8.80.

Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its position in uniQure NV by 68.5% in the second quarter. JPMorgan Chase & Co. now owns 14,174 shares of the company’s stock worth $104,000 after buying an additional 5,760 shares during the last quarter. Capital Fund Management S.A. acquired a new position in uniQure NV during the third quarter worth approximately $111,000. TFS Capital LLC increased its position in uniQure NV by 3.0% in the second quarter. TFS Capital LLC now owns 15,156 shares of the company’s stock worth $112,000 after buying an additional 437 shares during the last quarter. Princeton Alpha Management LP acquired a new position in uniQure NV during the second quarter worth approximately $120,000. Finally, Fox Run Management L.L.C. acquired a new position in uniQure NV during the second quarter worth approximately $122,000. 31.68% of the stock is owned by institutional investors.

uniQure NV Company Profile

uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.

5 Day Chart for NASDAQ:QURE

Receive News & Stock Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related stocks with our FREE daily email newsletter.